A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

Background Long‐term drug treatment of schizophrenia with typical antipsychotic drugs has
limitations: 25 to 33% of sufferers have illnesses that are treatment resistant. Clozapine is an …

Antipsychotic-induced sialorrhea carries a significant burden, but evidence-based treatment
guidance is incomplete, warranting network meta-analysis (NMA) of pharmacological …

Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Objective:
Clozapine treatment remains the gold standard for treatment‐resistant schizophrenia, but …

Guidelines for schizophrenia treatment have been created in various countries and have
been translated and used in Japan as well. However, the available drugs and their …

Background Schizophrenia and related disorders such as schizophreniform and
schizoaffective disorder are serious mental illnesses characterised by profound disruptions …

The first report demonstrating the therapeutic efficacy of an orally applied neurokinin-1
(NK1) receptor antagonist in depression was published 10 years ago. Although there were …

Background Clozapine is the most effective medication for treatment-refractory
schizophrenia. However, it has a high burden of adverse events, including common adverse …

Objectives: The objective of this study was to evaluate the prevalence and severity of
clozapine-induced hypersalivation, and assess the impact hypersalivation has on global …

Objectives To investigate the efficacy and tolerability of medications, such as mouthwash
use of 1% atropine sulfate and tropicamide drops, oral amitriptyline and amisulpride used for …